Related Experiment Videos
Clinical trial of pimozide
Summary
Pimozide and chlorpromazine showed similar effectiveness in treating chronic schizophrenia. Pimozide offered slight mood and motor improvements with fewer side effects, particularly beneficial for social integration.
Area of Science:
- Psychiatry
- Pharmacology
Background:
- Schizophrenia is a chronic mental disorder requiring long-term treatment.
- Comparing antipsychotic medications is crucial for optimizing patient outcomes.
Purpose of the Study:
- To compare the therapeutic effectiveness and tolerance of pimozide and chlorpromazine in chronic schizophrenic patients.
- To evaluate long-term outcomes for pimozide treatment.
Main Methods:
- A four-week comparative study of pimozide (1-4 mg/day) and chlorpromazine (100-200 mg TID).
- A twelve-month follow-up for pimozide treatment in chronic schizophrenics.
- Assessment of therapeutic activity, mood, motor function, and side effects.
Main Results:
- No significant global differences in therapeutic activity between pimozide and chlorpromazine.
- Pimozide showed slightly greater improvement in mood and motor activity.
- Chlorpromazine was associated with more drowsiness, dizziness, and extrapyramidal effects.
- Prolonged improvement was observed in 8 pimozide patients, with weight gain noted.
Conclusions:
- Pimozide offers advantages for chronic unsocialized schizophrenics due to its single daily dose, minimal side effects, and enhancement of social integration.
- Pimozide demonstrated a favorable profile regarding mental and physical performance compared to chlorpromazine.